Cyberonics, Inc.  

(Public, NASDAQ:CYBX)   Watch this stock  
Find more results for CYBX
49.53
+0.41 (0.83%)
Real-time:   11:39AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 48.90 - 49.69
52 week 36.82 - 56.73
Open 49.05
Vol / Avg. 44,489.00/366,655.00
Mkt cap 1.37B
P/E 30.55
Div/yield     -
EPS 1.62
Shares 27.64M
Beta 0.70
Inst. own 102%
Jun 5, 2013
Q4 2013 Cyberonics Earnings Conference Call - 9:00AM EDT - Add to calendar
Jun 3, 2013
Q4 2013 Cyberonics Earnings Release Add to calendar
Mar 12, 2013
Cyberonics at Barclays Healthcare Conference
Feb 27, 2013
Cyberonics at RBC Capital Markets' Healthcare Conference
Feb 27, 2013
Cyberonics at Citi Global Healthcare Conference
Feb 22, 2013
Q3 2013 Cyberonics Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '13) 2012
Net profit margin 21.03% 16.51%
Operating margin 32.60% 27.89%
EBITD margin - 29.70%
Return on average assets 21.85% 17.04%
Return on average equity 24.64% 20.10%
Employees 536 -
Carbon Disclosure Rating - -

Address

The Cyberonics Building 100 Cyberonics Boulevard
HOUSTON, TX 77058
United States - Map
+1-281-2287200 (Phone)
+1-281-2189332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Cyberonics, Inc. (Cyberonics) is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.

Officers and directors

Daniel J. Moore President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Gregory H. Browne Chief Financial Officer, Senior Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
David S. Wise Senior Vice President, Chief Administrative Officer, Secretary
Age: 57
Bio & Compensation  - Reuters
Milton Mayo Morris Ph.D. Senior Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Darren W. Alch Chief Compliance Officer, Vice President, General Counsel, Assistant Secretary
Age: 46
Bio & Compensation  - Reuters
Randal L. Simpson Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Mark S. Verratti Vice President - Global Sales
Age: 44
Bio & Compensation  - Reuters
Bruce H. KenKnight PhD Vice President - Emerging Therapies
Bio & Compensation  - Reuters
Bryan D. Olin Ph.D. Vice President - Clinical , Quality & Regulatory Affairs
Age: 45
Bio & Compensation  - Reuters
Hugh M. Morrison Non-Executive Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters